🇺🇸 Triptorelin Embonate in United States

51 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 7 reports (13.73%)
  2. Fatigue — 7 reports (13.73%)
  3. Weight Decreased — 7 reports (13.73%)
  4. Acute Kidney Injury — 5 reports (9.8%)
  5. Dyspnoea — 5 reports (9.8%)
  6. Diarrhoea — 4 reports (7.84%)
  7. Muscle Atrophy — 4 reports (7.84%)
  8. Neutropenia — 4 reports (7.84%)
  9. Pain In Extremity — 4 reports (7.84%)
  10. Pallor — 4 reports (7.84%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Triptorelin Embonate approved in United States?

Triptorelin Embonate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Triptorelin Embonate in United States?

Marco Lorenzo Bonu is the originator. The local marketing authorisation holder may differ — check the official source linked above.